Extension of preclinical research collaboration agreement with a top-10 large pharma company

Posted on Jul 10, 2017

Oslo (Norway), 10 July 2017 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company, initiated in September 2015. The extended evaluation period spans over six months, until the end of 2017, and may be further extended.   The […]

Interview about fimaCHEM at the Medica Trade Fair homepage 2017

Posted on Jul 5, 2017

An interview with Prof. Dr. med. Jörg Trojan about treatment of bile duct cancer and the fimaCHEM technology has been published at the Medica Trade Fair homepage. Prof Trojan is Head of Gastrointestinal Oncology at the Cancer Centre at the University Hospital Frankfurt and one of the investigators in the fimaCHEM Phase I study in bile […]

Minutes from Annual General Meeting 2017

Posted on May 29, 2017

Oslo, 29 May 2017 – The Annual General Meeting in PCI Biotech Holding ASA took place today, 29 May 2017. All proposals in the call were approved. The Board of Directors were reelected and consists of the following members until the next Annual General Meeting:   * Hans Peter Bøhn, chairman   * Kjetil Taskén, […]